Table 3.

Baseline Comparison of Untreated AN (E−) versus Treated AN (E+)

	E−(n=9)	E+(n=13)	p (E− vs. E+)
Age (y)	16. 8±0. 4	17. 2±0. 3	NS
Bone age (y)	16. 0±0. 3	16. 7±0. 2	NS
Weight (kg)	45. 2±2. 3	47. 5±1. 3	NS
BMI (kg/m2)	16. 7±0. 4	17. 4±0. 4	NS
Tanner stage (breasts)	4. 66±0. 23	4. 69±0. 13	NS
Amenorrhea duration (y)	0. 84±0. 13	0. 90±0. 19	NS
Exercise Activity (h)	16. 5±3. 3	15. 4±3. 1	NS
Calcium intake (mg)	2033±312	1756±231	NS
Vitamin D intake (IU)	622±93	460±78	NS
DXA Measures
Fat mass (kg)	6. 8±0. 8	9. 2±0. 8	NS
Lean mass (kg)	37. 3±2. 1	37. 7±1. 0	NS
Lumbar BMD (g/cm2)	0. 821±0. 028	0. 847±0. 020	NS
Lumbar BMD Z-score	−1. 53±0. 27	−1. 33±0. 20	NS
Biochemical Parameters
25(OH) vitamin D (ng/ml)	35. 6±4. 1	27. 7±2. 2	NS
PTH (pg/ml)	17. 8±3. 5	30. 4±4. 4	NS
Estradiol (pg/ml)	24. 3±3. 6	34. 3±5. 1	NS
24-hr UFC (mcg)	50. 4±15. 2	54. 5±10. 3	NS
IGF-1 (ng/ml)	259±37	219±21	NS
Leptin (ng/ml)	3. 0±1. 1	4. 9±0. 7	NS
P1NP (ng/ml)	107. 7±34. 6	90. 8±13. 5	NS
CTX (ng/ml)	0. 99±0. 09	0. 62±0. 08	0. 02
Sclerostin (ng/ml)	0. 483±0. 040	0. 427±0. 030	0. 27

NS: not significant